Experts Knowledge Share: Incorporating PARP inhibitors into prostate cancer clinical practice
Experts Knowledge Share: Incorporating PARP inhibitors into prostate cancer clinical practice
On-demand e-learning, video replay and slide set now available
On-demand e-learning, video replay and slide set now available
Prof. Fred Saad, Assoc. Prof. Tanya Dorff, Prof. Gerhardt Attard, Prof. Neeraj Agarwal
In our recent Experts Knowledge Share, world-renowned experts discussed case studies, reviewed the latest data and shared their views.
Guest expert Prof. Fred Saad joined GU CONNECT members Assoc. Prof Tanya Dorff, Prof. Gerhardt Attard, and Prof. Neeraj Agarwal, along with participants from around the world, to discuss incorporating PARP inhibitors into prostate cancer clinical practice.
GU CONNECT invites you to watch the video replay, download the accompanying slides, and take the e-learning using the blue button below the video to claim your CME credit.
Prof. Fred Saad
Professor and Chairman of Urology, Director of GU Oncology Raymond Garneau Chair in Prostate Cancer
University of Montreal Hospital Center, Canada
Canada
Assoc. Prof. Tanya Dorff
Medical Oncologist
City of Hope Comprehensive Cancer Center
United States (US)
Prof. Gerhardt Attard
Medical Oncologist
University College London Cancer Institute
United Kingdom (UK)
Prof. Neeraj Agarwal
Medical Oncologist
University of Utah Huntsman Cancer Institute
United States (US)
Incorporating PARP inhibitors into prostate cancer clinical practice
| 
78 min
|accreditation:
EACCME |
Dec 2022
download resources
This programme was made for you: your opinion matters
Share your feedback in just 4 clicks and help us to continue to create the content you need.
I agree that this educational programme:
Incorporating PARP inhibitors into prostate cancer clinical practice.
Video Chapters
Chapter 1 00:00 Scene-setting - Prof. Fred Saad
Chapter 2 05:23 Use of PARP inhibitors beyond the first-line setting in mCRPC - Prof. Fred Saad and Prof. Gerhardt Attard
Chapter 3 39:24 Use of PARP inhibitors in the first-line setting in mCRPC - Assoc. Prof. Tanya Dorff and Prof. Neeraj Agarwal
Chapter 4 1:09:50 Questions and panel discussion
Chapter 5 1:14:06 Future perspectives and summary - Prof. Fred Saad
Clinical Takeaways
-
PARP inhibitors are an important part of the treatment strategy for mCRPC patients
-
mCRPC patients who harbour HRR mutations benefit from PARPi monotherapy following progression on prior novel hormonal agents
-
Treatment with PARP inhibitors plus novel hormonal agents can provide combination benefits in mCRPC patients with or without HRR mutations
-
The future treatment landscape for prostate cancer patients will likely include the earlier introduction of PARPi's and treatment beyond patients with HRR/DRR mutations
This educational programme is supported by an Independent Medical Education Grant from AstraZeneca
GU CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from AstraZeneca, Bayer and Eisai Europe Limited.
Other programmes of interest
15 min
Other programmes developed by Assoc. Prof. Tanya Dorff
Assoc. Prof. Tanya Dorff
Medical Oncologist
City of Hope Comprehensive Cancer Center
United States (US)
Other programmes developed by Prof. Gerhardt Attard
Prof. Gerhardt Attard
Medical Oncologist
University College London Cancer Institute
United Kingdom (UK)
Other programmes developed by Prof. Neeraj Agarwal
Prof. Neeraj Agarwal
Medical Oncologist
University of Utah Huntsman Cancer Institute
United States (US)
